[1]
“Tirzepatide Across the Cardiovascular Continuum From HFpEF to cardiorenal protection with a dual GLP-1/GIP agonist”, d, vol. 4, no. 21, pp. 42–43, Jul. 2026, Accessed: Jul. 28, 2026. [Online]. Available: https://thediabzen.com/index.php/d/article/view/64